The Volga muscle-invasive bladder cancer study might have matched Keynote-905.
ApexOnco Front Page
Recent articles
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
What could be the four HengRui assets picked up by Bristol?
The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
GDC-1261 and INR731 enter phase 1, but how do they act?
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
The company now needs to carry out separate phase 2s of its G12D inhibitor VS-7375.
The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
